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ABSTRACT
Helicobacter pylori (H. pylori) is a microbe which cause chronic infection in human. Currently, the prevalence 
in developed countries continue to decrease, but the same does not happen in developing countries. Orofecal 
transmission and its connection with environmental condition is assumed to be its cause.
Impact of H. pylori infection in gastric mucosa is influenced by the bacteria pathogenesis which is able to 
survive in acid condition and causes inflammatory reaction. The diagnosis is differentiated through endoscopy 
or non-endoscopy depends on the alarm symptoms, local prevalence, pre-test probability, availability, cost and 
aim of examination.
Management of H. pylori depends on the high rate of clarithromycin resistence. In area with resistency 
prevalence below 20% triple therapy can still be used, while in increasing resistency area, use of four times 
daily therapy or other antibiotics such as levofloxacin and furazolidone can be considered.
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ABSTRAK
Helicobacter pylori (H. pylori) merupakan salah satu kuman yang dapat menyebabkan infeksi kronik pada 
manusia. Saat ini, prevalensi H. pylori di negara maju saat ini semakin menurun namun tidak demikian di 
negara berkembang. Transmisi oro-fekal dan keterkaitannya dengan kondisi lingkungan diperkirakan menjadi 
penyebabnya. 
Dampak infeksi H. pylori pada mukosa lambung dipengaruhi oleh patogenesis kuman yang mampu bertahan 
dalam lingkungan asam dan menimbulkan reaksi peradangan. Diagnosisnya dibedakan secara endoskopi atau 
non-endoskopi bergantung dari adanya tanda bahaya, prevalensi di daerah tersebut, probabilitas pre-tes, 
ketersediaan, biaya dan tujuan pemeriksaan. 
Tatalaksana H. pylori bergantung pada tingginya angka resistensi klaritromisin. Pada daerah dengan 
prevalensi resistensi di bawah 20% terapi triple masih dapat digunakan, sedangkan pada resistensi yang 
meningkat dapat dipertimbangkan pengunaan terapi quadruple atau antibiotik lain seperti levofloksasin dan 
furazolidone.
Kata kunci: Helicobacter pylori, diagnosis, terapi alternatif
INTRODUCTION
Since the discovery of Helicobacter pylori (H. 
pylori) until now, this bacteria has been one of the 
microbes causing chronic infection to human. This 
bacterial infection is associated with several upper 
gastrointestinal complaints, such as chronic gastritis, 
peptic ulcer, and gastric cancer.1 Prevalence study 
performed in a private hospital in Jakarta showed 
decrease tendency in the prevalence of H. pylori 
infection from 12.5 % in year 1998 to 2.9% in year 
2005.2
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Risk factors of this H. pylori infection is strongly 
associated to socioeconomic status and living 
environment condition in early age. Other factors, 
including residents density, number of siblings, bed 
sharing, lack of flowing clean water are associated 
with high incidence of this bacterial infection. Bacterial 
transmission pattern, through which route bacteria can 
infect is still unclear. Human to human transmission 
through fecal or oral, or oral/oral exposure is the 
most possible way.3 Till date, human is still the main 
infection site of H. pylori. Bacteria may survive in a 
long time underwater, which is proved by polymerase 
chain reaction (PCR) test in water reservoirs. Based 
on this findings, it is estimated that the transmission 
of H. pylori infection may happen through fecal-oral 
route, particularly in less hygienic water reservoirs, 
including swimming pool, raw vegetables or raw water 
consumption which are mostly found in developing 
countries.4 Currently, although the infection prevalence 
seem to decrease in some countries, H. pylori still 
become an important factor in peptic ulcer, gastric 
cancer, and dyspepsia symptoms.
DIAGNOSIS
As mentioned above that H. pylori  is  a 
microaerophillic bacteria living in extreme gastric 
environment, which is acidic. Bacteria has urease 
enzyme which can break urea into ammonia which is 
a base. Therefore, diagnostic procedure to prove the 
presence of H. pylori infection through direct method 
is very difficult, sometimes even requires endoscopic 
examination to obtain adequate specimen.1
Diagnostic method for H. pylori is divided into 2, 
which are: diagnosis using endoscopy or non-invasive 
diagnostic method which does not need endoscopy 
procedure. There is no single test which can completely be 
the gold standard for examination of H. pylori, therefore 
it needs correct considerations before choosing the 
diagnostic method to be performed. In choosing the test, 
some things need to be considered, including patients' 
clinical condition, the presence of alarm signs, the local 
prevalence of the disease, pretest probability of diagnostic 
tool, also the availability and cost from each test.
 ENDOSCOPIC DIAGNOSIS TEST
There are four tests which can be performed through 
endoscopy to diagnose H pylori infection. These tests 
are rapid urease test (RUT), histology, culture and PCR.
Rapid Urease Test
Rapid urease test (RUT) is a very specific diagnostic 
test for H. pylori and is used to detect bacteria through 
endoscopy.5 RUT can detect the presence of H. pylori 
through urease activity. Through endoscopy, after 
gastric biopsy is performed, the result of biopsy is 
placed on an agar medium which has been given 
urea solution, buffer, and sensitive pH indicator. In 
the presence of H. pylori, urease enzyme found in 
this bacteria will metabolize urea into ammonia and 
bicarbonate causing increase in pH which will be 
detected by pH indicator in the form of colour changes. 
Result can be seen within 1 x 24 hours. There are 
several commersial RUT test which all in average 
has sensitivity of > 90% and specificity of > 95%.6 
Sensitivity of this test can be increased by obtaining 
more biopsy samples, either in number or places.5 
Study in Indonesia using an RUT testing tool (Pronto 
Dry) revealed sensitivity of 69.7% and specificity 
up to 95.7%.7 Similar study using Pronto Dry test 
showed sensitivity up to 98.1% and specificity up to 
100%.7 Better results of sensitivity of the test may be 
influenced by several factors, including histopathology 
evaluation, biopsy standardization, both in location and 
number. This is proved by the fact that if the study only 
involved study in Jakarta and Bandung, the sensitivity 
may reach 95.7%.7
Treatment such as bismuth, antibiotic, and proton 
pump inhibitor may decrease microbe density and 
urease activity, which finally decrease the sensitivity 
of the RUT test. In a study, patient which received 
proton pump inhibitor drugs, sensitivity, specificity, 
positive predictive value and negative predictive 
value, this diagnostic test was 43.3%, 86.4%, 81.3%, 
52.8% respectively, compared to patient who has 
not received proton pump inhibitor, values obtained 
were 71.9%, 80%, 82.1%, and 69%, respectively.5 
It was recommended to stop the drug at least a 
week before examination. In patient who has ever 
received antibiotic and proton pump inhibitor therapy, 
distribution of H. pylori in the stomach is separately 
discrete, predominant colony shift to the proximal. 
Therefore, it was advised to take biopsy sample from 
two locations, particularly the corpus and antrum 
angle for RUT diagnostic test. Other thing which 
can decrease the sensitivity of the examination is the 
presence of acute ulcer. 
Histology
Histology examination from biopsy sample has an 
important role in the diagnosis of H. pylori. In histologic 
examination, we found H. pylori directly, thus many 
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stated that this examination can be considered as gold 
standard. However, this is not entirely correct because 
there is still heterogeneity in biopsy methods, amount 
of biopsy, colouring, and the ability of pathologist.6
In histology examination to detect the presence 
of H. pylori in biopsy specimen, it is advised that 
specimen is taken from non-ulcer part. However in 
gastric ulcer patient, biopsy specimen can be taken 
from several location, including from the edge of the 
ulcer. Effectivity of specimen collection from ulcer 
edge is still controversial. Based on the report of a 
study on effectivity of histology examination in ulcer 
edge in patients with gastric ulcer without bleeding, it 
was concluded that histology examination from ulcer 
edge is inadequately sensitive for H pylori diagnosis 
in gastric ulcer patients, particularly if ulcer is found 
in more proximal area or malignant ulcer.8
Due to the number of and density degree of 
microbes vary between individuals who has been 
exposed to treatment, biopsy is needed in enough 
amount for accurate diagnosis. It is suggested that 
at least 3 biopsy are taken from angle, major antrum 
curve, and major corpus curve.5 Similar to RUT 
examination, sensitivity of this examination is based 
on previous treatment exposure. Sensitivity, specificity, 
positive predictive value, negative predictive value, 
and diagnostic accuracy from histology examintion 
decrease after exposure to acid inhibitor. After 4 weeks 
of omeprazole administration, microbe colony density 
in corpus and antrum decrease, but there is an increase 
in the density of colony in the fundus. Migration of H. 
pylori from antrum to the fundus is associated with 
decrease activity of gastric antrum.5
One of the advantages of this examination is that it 
can also evaluate pathological changes associated to 
Helicobacter infection, such as: signs of inflammation, 
atrophy, intestinal metaplasia or even signs of 
malignancy.6
Culture
Culture is one of the specific diagnostic methods. 
It is not only important in finding Helicobacter 
bacteria, but it is also useful in testing the sensitivity 
of bacteria to antibiotic.6 Nonetheless, culture is not 
a sensitive examination like RUT or even histology. 
Culture technique for H. pylori is difficult to perform 
and cause a huge cost. Difficulties in culture include it 
needs fresh sample and fixation has not been performed 
for histopathology examination. Inaccuracy in sample 
handling during transport may also cause negative false 
results. Sample is not allowed to contact with air and 
put inside saline solution (viable for 4 hours) or may 
also be sent using particular semisolid agar medium.9 
Culture examination can be performed up to 24 hours 
after biopsy if sent using that particular medium.9
Polymerase Chain Reaction
Polymerase chain reaction (PCR) is an examination 
which use DNA amplification technique to identify 
base arrangement in H. pylori. This diagnostic method 
is very specific and more sensitive compared to other 
endoscopic diagnostic tests.6 Other advantage from 
PCR is it can detect the changes in DNA arrangement 
or mutation which is associated with resistency.
In their study, Weiss et al analyzed the effectivity 
of PCR examination to  Campylobacter like-organism 
(CLO) test and immunohistochemistry. In the 
examination with gastric biopsy sample, all biopsy 
with positive CLO test and immunohistochemistry, 
positive results on PCR examination is also obtained. 
Even PCR can still detect patient who has negative 
results of CLO test and immunohistochemistry. Weiss 
et al also succeed in associating between PCR results 
with degree of inflammation due to H. pylori.10
NON-ENDOSCOPY DIAGNOSTIC TEST
Currently there are three non-invasive diagnostic 
tests to detect the presence of H. pylori. Fecal test 
antigent, urea breath test (UBT), and antibody test 
can detect the presence of immunological reaction in 
infection, both in serum and urin.
Fecal Test Antigen
Fecal test antigen (FTA) detects the presence of 
H. pylori antigen in the faeces using anti H. pylori 
polyclonal antibody.6 This faeces antigen examination 
is based on immunoassay technique through enzyme 
linked immunosorbent assay (ELISA). Currently, it 
is also been developed faeces antigen examination 
using monoclonal antibody. In H. pylori new antigen 
(catalase) has been found, which is more stable and 
examination using monoclonal antibody to this antigen 
can give out faster results, ranging around 70 minutes, 
also more specific compared to the method using 
polyclonal antibody.11
This test similar to UBT is useful in detecting active 
Helicobacter infection and helpful in the treatment 
evaluation. The use of this test with polyclonal 
antibody has good sensitivity, specificity, positive 
predictive value, and negative predictive value in 
examination before treatment, but not so good during 
therapy evaluation.6 The use of monoclonal antibody 
has sensitivity, specificity, positive predictive value, 
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and negative predictive value more than 90% before 
and after treatment.6 A study on validation of faeces 
antigen test with UBT as gold standard was performed 
in Brazile, in which 95 consecutive patient, who 
were both asymptomatic and experienced dyspepsia 
symptoms. Results of this study revealed the sensitivity 
reached 88% (95% CI = 75.7 - 95.5%) and specificity 
reached 87.5% (95% CI = 74.7-95.3%) with kappa 
index up to 0.75, therefore it was concluded that 
this faeces antigen test can be an alternative in UBT 
examination, particularly in developing countries.12
A study on faecal antigen test which is conducted 
in Indonesia using HpSA test with cut off point 0.27 
obtained sensitivity 66.7% and specificity 78.9%. 
Results of this test can be used for diagnosis because 
the specificity approached the specificity of other 
test, but cannot be used for screening due to its low 
sensitivity.13
In examination in low probability pretest 
community, FAT has better accuracy rate compared 
to antibody examination. Nonetheless, similar to UBT, 
this test is so much influenced by the use of bismuth, 
antibiotic, and proton pump inhibitor. FAT specificity 
also decrease in patients with bleeding peptic ulcer, 
therefore, single diagnostic test is not recommended.6
Urea Breath Test
Urea breath test (UBT) can be considered as 
one of the gold standard examinations for H. pylori 
through endoscopy. Similar to RUT, UBT is helpful 
in identifying active infection of H. pylori through 
urease activity. With the presence of H. pylori, urea 
compound which has been labelled with 13C non-
radioactive isotope or even 14C radioactive isotope 
will be metabolized by urease to produce labelled CO2 
compound, which can be counted quantitatively. 13C 
non-radioactive isotope will be a choice to be used in 
female and children.6
For after treatment evaluation, UBT also give out 
good and accurate result. Therefore, similar to RUT, 
this test is very influenced by previous treatment and 
thus, it was suggested to stop the use of bismuth and 
antibiotic at least 28 days and proton pump inhibitor 
1–2 weeks before UBT is performed.6 By stopping 
proton pump inhibitor in 2 weeks before UBT, it is 
expected that there is regrowth of bacteria.14 Regarding 
administration of H2 receptor antagonist is still 
controversial, however several laboratories suggested 
drugs ceasation 24-48 hours before examination is 
performed. Use of citric acid before labelled urea 
consumption may help decrease false negative.14 
Citric acid can inhibit gastric emptying and decrease 
gastric pH. Unlike proton pump inhibitor and H2 
antagonist, antacide need not to be discontinued as it 
does not effect this examination.14 Besides influenced 
by previouse drug use, the weaknesses of this test are 
costly and requires special equipment.
Antibody Test
Antibody test is one of the non-invasive diagnostic 
tests based on the detection of specific IgG antibody 
to H. pylori.6,14 IgG antibody appears approximately 
21 days after H. pylori infection and can stay in quite 
long time. Antibody to H pylori can be measured 
quantitatively using ELISA technique, reverse flow 
immunochromatopgraphy or passive hemaglutination. 
The advantages of this examination in addition to the 
cost is not too high, it is widely available and results 
can be obtained in short time. Furthermore, antibody 
test is the only diagnostic tool which is not influenced 
by local changes in the stomach due to the use of 
drugs, therefore it is not required to stop therapy given 
to overcome gastrointestinal symptoms, including 
bismuth, proton pump inhibitor or antibiotic use. 
Nonetheless, there is factor which limits the use in the 
community, such as the positive predictive value is 
influenced by disease prevalence in the community.14 
In community with low prevalence, the positive 
predictive value is also low. Another common problems 
are the antigen type being used in an area differs to the 
other area, therefore it cannot be used in other location.
Serology diagnostic test of H. pylori with local 
antigen in Indonesia has been produced in laboratories 
in Mataram, West Nusa Tenggara. Diagnostic test with 
equipment developed by Sumohardjo et al using local 
antigen obtained sensitivity of 96% and specificity 
85.7%.15 Epidemiology study using this tool has been 
conducted in Jakarta and resulted that the prevalence 
of H. pylori reaching 52.3%.7
Urine Antibody
H. pylori antibody examination from urine is 
reported to be one of the diagnostic tests which is 
reliable for adults. The base of this examination is the 
finding of H. pylori antibody in body liquid other than 
serum. IgA antibody H. pylori can be found in gastric 
secretion of patients who are infected with H. pylori. 
IgA and IgG H. pylori antibody can be found in saliva 
and gastric secretion. IgG H. pylori antibody in urine 
can also be found and its association with H. pylori in 
human.16 However, level of H. pylori antibody in urine 
is much more lower compared to its level in the serum. 
This low level causes the test depend on the patients' 
kidney function, urine sediment, and urine pH.
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Urine antibody test method using immunoassay 
method obtained sensitivity and specificity reaching 
95.9% and 90%.16 Several fear regarding the influence 
of proteinuria to sensitivity and specificity of this tool 
is disproved through the study performed by Yamamoto 
et al, which showed that accuracy rate still above 95 
% if used in patients with proteinuria.17
MANAGEMENT OF HELICOBACTER PYLORI
Management with triple therapy is still the main 
treatment for H. pylori infection. Besides triple 
therapy, four times daily therapy can also be used in 
region with high resistency of clarythromycin. Based 
on the therapy guidelines in United States, triple 
therapy uses proton pump inhibitor, clarythromycin, 
and amoxicillin or metronidazole for 14 days, while 
four times daily therapy uses H2 receptor antagonist, 
bismuth, metronidazole, and tetracycline for 10-14 
days.6 Consensus on treatment of  H. pylori in Europe 
also recommend combination therapy of proton pump 
inhibitor (PPI)-clarythromycin and amoxicillin or 
metronidazole in region with clarythromycin resistency 
rate below 15–20%.14 Generally, there is decrease in 
the efficacy of this clarythromycin based triple therapy, 
which may be caused by adherence, high level of 
gastric acidity, high bacterial colony, microbe strain 
type, and most important is resistency of H. pylori to 
clarythromycin. Resistency to clarythromycin increases 
globally. In Europe, resistency rate increases drom 9% 
in 1998 to 17.6% in 2008-2009. This resistency rate 
increases almost in all part of Europe, however in some 
places such as Middle, West, and South Europe, the 
resistency increases more than 20%.14 In regions where 
it has been known that the resistency rate exceeds 15–
20% administration of clarythromycin based therapy 
need to be avoided.
Alternative therapy which can be given to patients 
with H. pylori infection beside clarythromycin-based 
therapy and bismuth-based therapy is sequential 
therapy. This therapy can be used particularly if first 
line antibiotic has been given or there is previous 
exposure to that antibiotic, or it has been known that 
the resistency rate to clarythromycin exceeds 20%.14
As has been mentioned above that recommended 
first line therapy in United States are clarythromycin-
based and four times daily-bismuth therapy. If used 
properly, the eradication rate may reach 70-80%.6 In 
triple therapy other than using PPI and clarythromycin, 
in combination with second antibiotic which is 
amoxycillin is also used. However, as we know that 
the wide use of amoxycillin particularly as antibiotic 
in the management of upper respiratory tract infection, 
it is also be feared that resistency to amoxycillin may 
happen. Thus, amoxycillin may be substituted by 
metronidazole. Use of amoxycillin or metronidazole 
has similar effectivity. In a meta-analysis comparing 
erradication therapy by using PPI-clarythromycin-
amoxycillin and PPI-clarythromycin-metronidazole 
revealed equivalent eradication rate (71% vs. 65%) 
which is statistically not significant.18 Hence, as 
second antibiotic in triple regimen therapy, amoxycillin 
or metronidazole can be used depend on the local 
resistency pattern.
To increase eradication rate, it is suggested to 
increase of proton pump inhibitor dose to be twice daily 
high dose. Meta-analysis of 13 studies revealed that use 
of proton pump inhibitor twice daily in clarythromycin-
based therapy was more effective compared to once 
daily dose one. This study exhibited that the use of high 
dose PPI can increase recovery (cure) rate of 6–10% 
compared to the standard dose.14 History of routine 
consumption of PPI before diagnosis of H. pylori does 
not change the duration and dose of therapy which will 
be given. However, in patients who were proved to suffer 
from intolerance to PPI, H2 receptor antagonist can be 
given in substitute.
Treatment duration also become an important thing 
in eradication of H. pylori infection. Lengthening of 
treatment duration from 7 days to 10-14 days is said to 
increase eradication rate, but in the other hand increase 
health cost. Study using combination of rabeprazole, 
clarythromycin, and amoxycillin failed to show 
significant difference of eradication rate by lengthening 
duration of treatment from 7 to 10 days (77% vs. 78%).20 
However, another meta-analysis comparing treatment 
duration of 7 and 14 days using triple therapy concluded 
that lengthening duration for 14 days might increase 
eradication rate.19 Maastricht IV Conference in Europe 
also summarized that lengthening treatment duration to 
10-14 days may increase eradication rate up to 5-6%.14 
Therefore, although some things need to be considered, 
including cost, adherence, and arising side effects, it is 
suggested that treatment is administered for 14 days. 
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patient  infected with metronidazole resistent bacteria 
who received four times daily therapy actually still 
has eradication rate exceeding 80%, which was 80.4% 
compared to if previously not proven to be infected 
with metronidazole resistency, in which eradication 
rate can reach 87.7%. In patient with clarythromycin 
resistent bacteria, the use of clarythromycin-based 
therapy eradication rate decreases into 21.4 %.24
Therapy regiment most frequently used is the 
clarythromycin-based therapy, therefore failure therapy 
with this regiment can be resolved with administration 
of bismuth four times daily regiment, consisting of PPI, 
tetracycline, metronidazole, and bismuth. Based on the 
guidelines published by European Helicobacter Study 
Group (EHSG) and Maastricht IV consensus stated 
that four times daily therapy using bismuth, including 
second line therapy, and used effectively in patients with 
first line treatment failure. Bismuth four times daily 
can also be used as first line in region with high rate of 
clarythromycin resistence.14 But, as has been mentioned 
above that the weakness of bismuth regiment therapy is 
the more number of pils, more frequency administration, 
and more frequent occurence of side effects. 
Alternative Treatment of Helicobacter pylori
Second line therapy which can be used other than 
bismuth is the use of rifabutin, an antibiotic which 
has long been used in tuberculosis treatment known 
to be useful as an alternative to clarythromycin. A 
study in Australia involving 130 patients failed with 
clarythromycin-based treatment, received rifabutin 150 
mg, pantoprazole 80 mg, and amoxycillin 1-1.5 g per 
day for 12 days. Eradication rates in intention to treat 
and per protocol with this regiment reach 90.8% and 
90.8%, respectively.25 The most common side effects 
which occur from rifabutin administration are rash, 
gastrointestinal symptoms, including nausea, vomiting, 
dyspepsia, and diarrhea.25
Furazolidone, antibiotic often used in management 
of giardiasis, cholera, and bacterial enteritis also play 
role as an alternative to clarythromycin, metronidazole, 
Table 1. First line regiment of Helicobacter pylori eradication6
Regiment Duration Eradication rate Comments
PPI twice daily, clarythromycin 500 mg twice daily, amoxycillin 1000 
mg twice daily
10–14 days 70–85% In patients who has never received 
macrolide, not allergic to penicillin
PPI twice daily, clarythromycin 500 mg twice daily, metronidazole 
500 mg twice daily
10–14 days 70-85% In patients allergic to penicillin, 
intolerant to bismuth
Bismuth 525 mg four times daily, metronidazole 250 mg twice daily, 
tetracycline 500 mg four times daily, ranitidine 150 mg twice daily 
atau PPI fourth-twice daily
10–14 days 75-90% In patients allerhic to penicillin
PPI + amoxycillin 1 g twice daily are recommended
PPI, clarythromycin 500 mg twice daily, tinidazole 500 mg twice 
daily
5 > 90%
PPI: proton pump inhibitor
Use of four times daily therapy as an alternative to 
three times daily therapy is proved in a meta-analysis 
study. Comparison of three times daily and four times 
daily therapy, either per protocol (85% vs 87%) or 
intention to treat (79% vs 80%) showed there was no 
significant difference through statistic in the ability to 
eradicate H. pylori.21 One of the difficulties of using 
four times daily therapy associated with the amount 
and duration of treatment administration. Frequency 
of moderate to severe side effect occurence in bismuth 
therapy administration is not more common compared 
to clarythromycin-based therapy.21
Both first line therapy above seem to be quite 
promising in H. pylori eradication, however the 
eradication rate in studies mentioned above generally 
showed less than 85%.6 Therefore, alternative 
therapy is developed, which was sequential therapy. 
Multicentre study in Taiwan which compared 10 days, 
14 days sequential therapy, and 14 days three times 
daily therapy showed although there was no difference 
statistically, sequential therapy has better eradication 
rate (90.7% vs. 87% vs. 82.3%).22
Eradication of H. pylori often failed, this is 
influenced by patients' adherence or even bacteria 
resistency. When confronted with treatment failure, 
antibiotic administration in the previous regiment 
was advised to be avoided. Due to the high cost 
and rare availability, culture and sensitivity test is 
not performed, unless there is failure in at least two 
regiments of therapy.
Resistency become one of the most important 
thing in therapy failure. Multicentre study in United 
States between 1998 to 2002 obtained metronidazole 
resistency rate of 25% compared to clarythromycin 
resistency rate of 13%.23 Although metronidazole 
resistency rate is higher, therapy failure is mostly 
caused by clarythromycin resistency. Metronidazole 
resistency is more relative, which is a resistency 
which can be resolved by increasing the dose of 
metronidazole or change regiment if therapy into four 
times daily regiment.6 From a study, it is stated that in 
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and amoxicillin.6 Furazolidone has bacteriostatic and 
bactericidal to negative and positive gram bacteria, also 
absorbed well in gastrointestinal tract. This drug also 
has activity to H. pylori and till date, furazolindone 
resistency strain of bacteria is still rare to be found, 
therefore, this drug is a potential option to treat failure 
in H. pylori treatment.26 Other drugs which can be 
used as an alternative treatment are levofloxacin, 
fluroquinolone group antibiotic which through invitro 
proved to have activity to H. pylori. Combination 
of PPI, levofloxacin, and amoxycillin which has 
been evaluated as second and third line treatment in 
management of H. pylori. Meta-analysis study on the 
use of levofloxacin based and four times daily therapy 
in patient who failed with first line therapy resulted 
that the use of levofloxacin based therapy for 10 days 
is more effective compared to 7 days (81% vs. 73%; 
p < 0.01).27 From this meta-analysis, eradication rate 
in levofloxacin-based and four times daily therapy 
also has been evaluated. Statistically, there is no 
significant difference, but levofloxacin based therapy 
has better eradication rate  (81% vs. 70 %; OR = 8; 
95% CI = 0.94-3.46). If evaluated from the arising 
side effects, levofloxacin-based therapy has lower side 
effects (95% CI = 0.16-0.46; OR = 0.27).27 Therefore, 
it can be concluded that levofloxacin-based therapy 
can be used as an alternative therapy or therapy for 
those who failed with the first line. Further, in Brazil, 
it has also been administered combination therapy 
of furazolidone, levofloxacin, and lansoprazole as 
treatment choices in cases where initial treatment 
of H. pylori failed. In a study involving 48 patients, 
performed per protocol and intention to treat analysis 
showed eradication rate reached 89% and 88% even 
in patients who failed initial treatment and were given 
this combination, eradication rate reached 100%.26 
Therefore, combination of these three drugs can be 
chosen in failure of first line treatment of H. pylori 
particularly in new patients who experienced one time 
failure.
As has been mentioned above regarding the 
increase of resistency rate to clarythromycin and 
metronidazole caused decrease in eradication rate 
of three or four times daily regiment administration. 
Table 2. Second line therapy in persistent Helicobacter pylori based on Maastricht IV Consensus6
Regiment Duration Eradication rate Comments
PPI four times daily, tetracycline, pepto-bismol, 
metronidazole four times daily
 7 68% (95% CI = 62-74%) Affordable, easy retrieved, but more frequent 
consumption and more number of pills
PPI, amoxycillin 1 g twice daily, levofloxacin 500 
mg four times daily
 10 87% (95% CI = 82-92%)
PPI: proton pump inhibitor
Therefore, currently sequential regiment has been used, 
particularly 10 days regiment therapy administration, 
divided into first 5 days therapy with proton pump 
inhibitor and amoxycillin 1 g twice daily continued 
with 5 days clarythromycin 500 mg twice daily and 
tinidazole 500 mg twice daily. Administration with this 
method is expected to increase the treatment success 
rate because initial administration of amoxycillin 
will help to weakened bacterial cell wall which will 
decrease resistency to clarythromycin. 
In a study which tried to compare this sequential 
regiment with three times daily therapy for 7, 10, 
and 14 days, it was found that eradication rate with 
sequential therapy reached 82%, compared to three 
times daily therapy for 7, 10, and 14 days which 
reached 75.7%, 81.9%, and 84.4%, respectively.28 
From this result, there was no significant difference on 
the eradication rate, thus the use of sequential therapy 
could be used to prevent the increasing resistency rate 
to clarythromycin and metronidazole.28
Other studies as mentioned above regarding 
comparison of sequential regiment for 14 days, three 
times daily therapy for 7 and 14 days also did not 
showed statistical difference, although sequential 
therapy has better eradication rate compared to triple 
therapy administration, which were 90.7% and 87% 
compared to 82.3%.22 From both studies above, it can 
be concluded that sequential therapy can be a chance 
for main treatment of H. pylori. 
Evaluation on results of treatment is important to 
be performed for further treatment and management of 
the patient. Not all patient who undergo treatment have 
to experience eradication test. Bacterial eradication 
test is performed in patients with H. pylori with 
ulcer, patient who underwent gaster resection, patient 
with mucosa-associated lymphoid tissue (MALT) 
lymphoma, and patient with dyspepsia complaints 
which did not subside after test-and-treat strategy. 
After treatment administration, eradication need 
to be confirmed with UBT or FAT.29 Monitoring of 
this treatment is performed 4 weeks after treatment 
is completed.29 Serology antibody test cannot be 
used to evaluate therapy because IgG which is the 
basis of the examination can last for a long duration. 
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14. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon 
ATR, Bazzoli F, et al. Management of H. pylori infection-the 
Maastricht IV/Florence consensus report. Gut 2012:61:646-64
15. Sumohardjo S, Gunawan S, Muttaqin Z, Muliaty D, Suparyatmo 
JB, Budyono M, et al. Pentingnya antigen strain lokal untuk 
pembuatan kit diagnostik untuk deteksi antibodi terhadap 
Helicobacter pylori. Dexa Media 1995;8:23-6.
16. Alemohammad MM, Foley TJ, Cohen H. Detection of 
immunoglobulin G antibodies to Helicobacter pylori in 
urine by an enzime immuniassay method. J Clin Microbiol 
1993;31:2174-7.
17. Yamamoto T, Kojima K, Sanaka M, Ishii T, Osaki Y, Tsutsumi 
H, et al. Reliability of rapid urinary test for antibody to 
Helicobacter pylori in adult patients with proteinuria. Diagn 
Microbiol Infec Dis 2006;54:105–8. 
18. Gisbert JP, Gonzalez L, Calvet X, Garcia N, Lopez T, 
Roque M, et al. Proton pump inhibitor, clarithromycin and 
either amoxycillin or nitroimidazole: a meta-analysis of 
eradication of Helicobacter pylori. Aliment Pharmacol Ther 
2000;14:1319-28 
19. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. 
A meta-analysis of short versus long therapy with a proton 
pump inhibitor, clarithromycin and either metronidazole or 
amoxycillin for treating Helicobacter pylori infection. Aliment 
Pharmacol Ther 2000;14:603–9. 
20. Vakil N, Lanza F, Schwatrz H, Barth J. Seven-day therapy for 
Helicobacter pylori in the United States. Aliment Pharmacol 
Ther 2004;20:99–107. 
21. Gene E, Calvet X, Azagra R. Triple vs. quadruple therapy 
for treating Helicobacter pylori infection: an updated meta-
analysis. Aliment Pharmacol Ther 2003;18:543–4.
22. Liou JM, Chen CC, Chen MJ, Chen CC, Chang YH, Fng YJ, 
et al; for the Taiwan Helicobacter Consortium. Sequential 
versus triple therapy for the first-line treatment of Helicobacter 
pylori: a multicentre, open label, randomised trial. Lancet 2012 
Nov 15 [cited 2012 Dec 12]. Available from: URL: http://
dx.doi.org/10.1016/S0140-6736(12)61579-7.
23. Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, 
Friedman C, et al. Antimicrobial resistance incidence and risk 
factors among Helicobacter pylori-infected persons, United 
States. Emerg Infect Dis 2004;10:1088–94.
24. Laine L, Hunt RH, el-Zimaity H, Nguyen B, Osato M, Spenard 
J. Bismuth-based bismuth quadruple therapy using a single 
capsul of bismuth biskalcitrate, metronidazol and tetracycline 
given with omeprazol versus omeprazol, amoxicillin and 
chlarithromycin for eradicaton of H. pylori in duodenal ulcer 
patients: a prospective, randomized North American Trial. 
Am J Gastroenterol 2003;98:56-7.
25. Borody TJ, Pang G, Wettstein AR, Clancy R, Herdman K, 
Surace R, et al. Efficacy and safety of rifabutin-containing 
rescue therapy for resistant Helicobacter pylori infection. 
Aliment Pharmacol Ther 2006;23:481-8.
26. Eisig JN, Silva FM, Barbuti RC, Rodriguez TN, Malfertheiner 
P, Filho MJ, et al. Efficacy of a 7-day course of furazolidone, 
levofloxasin, and lansoprazole after failed H. pylori 
eradication. BMC Gastroenterol 2009;9:38.
While in certain cases, such as gastric ulcer and 
MALT lymphoma, monitoring is performed through 
endoscopy and tissue biopsy.
CONCLUSION
H. pylori is a chronic infection in gastrointestinal 
which is responsible to the emergence of upper 
gastrointestinal tract complaints. Disease detection 
and prompt treatment are needed to decrease morbidity 
and prevent the development of malignancy. Current 
available modality therapy received huge challange, 
which is the developing resistency rate to standard 
therapy of H. pylori infection, therefore alternative 
therapy is needed to eradicate the disease.
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